Cancer Survivors

This research aims to understand how patients with cancer respond to COVID-19 vaccination by studying the levels of protective antibodies over time. The focus is on individuals with solid organ malignancies receiving various anti-cancer treatments such as chemotherapy, targeted therapy, and immunotherapy, as well as those who have been disease-free for at least six months. Since cancer patients were excluded from initial vaccine trials, this study seeks to fill knowledge gaps about vaccine safety and effectiveness in this group. Participants include cancer patients who are either undergoing active treatment or are disease-free for six months or more. They are grouped based on their treatment type: chemotherapy, targeted therapy, immunotherapy, or disease-free status. The study involves monitoring antibody trends related to COVID-19 infection and vaccination at multiple time points over a 12-month period. During the study, researchers will collect blood samples to measure neutralizing and spike antibody levels every three months for up to one year. Participants will be followed to track their immune response depending on their cancer treatment and biological aging status. The study will also assess how antibody levels change over time and correlate with different treatments and patient characteristics. Safety and consent are carefully monitored throughout the trial.

Researchers are evaluating the potential usefulness of 18F-FAPI-04 positron emission tomography/computed tomography (PET/CT) and positron emission tomography/magnetic resonance imaging (PET/MR) for diagnosing primary and metastatic cancer lesions, detecting recurrence, and assessing pathological response across various cancer types. The study is observational and aims to assess how well these imaging methods perform compared to standard diagnosis using histopathology and follow-up. Participants with different types of cancer undergo imaging with 18F-FAPI-04 PET/CT and PET/MR scans. The tracer 18F-FAPI-04 is injected into patients before the scans. Tumor uptake is measured by maximum standard uptake value (SUVmax) and tumor to background ratio (TBR). The imaging results are compared using sensitivity, specificity, positive predictive value, negative predictive value, and accuracy to evaluate diagnostic performance. During the study, participants are assessed through these imaging procedures to monitor tumor presence, recurrence, or response to treatment. The primary outcome is the diagnostic performance evaluated over one year. The study includes participants aged 18 to 90 years and involves informed consent and ethical approval. The total duration and follow-up details are based on imaging and clinical evaluations to confirm findings.

Researchers are evaluating the use of 18F-FDG PET/CT imaging to detect breast cancer metastases that conventional imaging methods like CT and bone scintigraphy might miss. This study focuses on women diagnosed with stage II/III or locoregional recurrent breast cancer, aiming to see if this imaging can improve disease staging and influence treatment decisions. It also explores how imaging and molecular characteristics may relate to patient outcomes such as overall survival and progression-free survival. Participants will undergo an 18F-FDG PET/CT scan in addition to the usual CT and bone scintigraphy imaging as part of their cancer assessment. The study includes patients with newly diagnosed high-risk breast cancer or suspected/proven locoregional recurrent breast cancer. The main goal is to determine if the PET/CT scan leads to changes in staging or treatment plans compared to conventional imaging alone. During the study, researchers will collect imaging data, including PET parameters and CT/MRI measurements, as well as blood and tumor samples for molecular analysis. They will monitor changes in cancer staging and management over five years, along with overall survival. Participants' health status will be assessed using the ECOG performance scale, and safety and outcomes will be followed throughout the study period, which runs until 2032.

Researchers are evaluating the side effects and optimal dose of a radioactive antibody agent called 211At-BC8-B10 in combination with donor stem cell transplant for patients with high-risk acute leukemia or myelodysplastic syndrome that has relapsed or is not responding to treatment. This phase I/II study aims to understand how 211At-BC8-B10, a monoclonal antibody that may affect cancer cell growth, works alongside chemotherapy, total body irradiation, and stem cell transplant to treat these conditions. Participants receive a preparative regimen including an infusion of 211At-BC8-B10 over 6 to 8 hours, followed by fludarabine and cyclophosphamide given intravenously on specific days, and total body irradiation before transplant. On transplant day, patients undergo peripheral blood stem cell or bone marrow transplant. After transplant, patients are given medications cyclophosphamide, mycophenolate mofetil, and tacrolimus to reduce the risk of graft versus host disease. They also receive granulocyte colony-stimulating factor until their white blood cell counts recover. During the study, participants have bone marrow biopsies, aspirations, and blood samples collected to monitor their condition. Follow-up visits occur at 100 days, and at 6, 9, 12, 18, and 24 months after treatment. Researchers measure outcomes such as serious toxic side effects, remission rates, engraftment success, donor cell presence, immune recovery, graft versus host disease, survival, and disease-free survival. The study is sponsored by the Fred Hutchinson Cancer Center and includes adults aged 18 to 75 years.

This research aims to evaluate the use of a new imaging agent called 68Ga-ICAM-1pep in cancer patients undergoing radiotherapy. Researchers want to see if this agent can help predict the abscopal effect, a phenomenon where radiotherapy affects tumors outside the treated area. The study focuses on patients with various cancers such as lung, esophagus, and cervical cancer, and it is an early-phase clinical trial investigating this new approach. Participants will receive a single intravenous dose of 2.96 MBq/kg of 68Ga-ICAM-1pep. PET/CT scans will be performed about one hour after the injection. There are two groups: patients who have not yet received radiotherapy and those who have completed radiotherapy. Imaging will be done before and during radiotherapy to observe tumor responses. During the study, participants will undergo PET/CT scans covering from the head to the upper thigh. Researchers will measure the standardized uptake values (SUVs) of 68Ga-ICAM-1pep before treatment and monitor changes during radiotherapy, about 3 to 4 weeks after it begins. The study includes monitoring for compliance with imaging procedures and overall safety until the study ends in late 2025.

Researchers are evaluating the uptake characteristics of 68Ga-NYM096 PET/CT imaging in various types of tumors, including both primary and metastatic cancer lesions. This prospective, single-center study aims to provide important insights into how different tumors take up this imaging tracer, helping to identify the most promising uses of 68Ga-NYM096 PET/CT for future cancer diagnosis and treatment assessment. Participants will receive a single intravenous dose of 68Ga-NYM096, with the amount adjusted based on body weight. After injection, a whole-body PET/CT scan will be performed approximately 45 to 75 minutes later to capture detailed images of tumor uptake. The study focuses on quantitative analysis of tracer uptake in cancer lesions, measuring factors such as lesion number, maximum standardized uptake value (SUVmax), and tumor-to-background ratio. During the study, participants will undergo the PET/CT imaging procedure and provide informed consent. Researchers will analyze the images to assess tracer uptake characteristics in confirmed tumors. Safety and compliance with study procedures will be monitored. The main outcome is the quantitative assessment of tumor lesions on the 68Ga-NYM096 PET/CT scan, evaluated from study completion to one month after. The study plans to enroll 120 patients with confirmed cancer diagnoses and will follow ethical guidelines throughout the research.

Researchers are studying the stimulator of interferon gene (STING) protein, which plays an important role in the immune system's ability to detect tumors. This trial focuses on evaluating a new imaging agent called [68Ga]Ga-Sa-DABI-4, designed to noninvasively detect STING expression in the tumor environment using positron emission tomography (PET). The study aims to assess the safety, distribution in the body, and potential usefulness of this imaging agent for cancer patients. Participants will receive one intravenous injection of the investigational drug [68Ga]Ga-Sa-DABI-4 during the study. This single administration is followed by PET imaging to monitor how the agent interacts with the tumor. The study is conducted in an early phase 1 design, focusing on initial safety and diagnostic capabilities. During the trial, participants will undergo PET scans to evaluate the diagnostic effectiveness of the imaging agent within 15 days after injection. Researchers will monitor safety and how the drug distributes throughout the body. The study includes patients suspected of having or newly diagnosed with malignant diseases. Participation involves a single dosing and imaging session, with safety and diagnostic data collected during this period.

Researchers are evaluating a new biobehavioral intervention called Goal-focused Emotion-Regulation Therapy (GET) for Latino/Hispanic young adult males who survived cancer diagnosed between ages 15 and 39. This study compares GET to an active control called Individual Supportive Listening (ISL). The goal is to improve distress symptoms, emotional regulation, goal navigation skills, and reduce stress-related biological markers. The trial builds on earlier research showing a high risk of distress and adverse outcomes in young Hispanic/Latino cancer survivors, aiming to address psychological and biobehavioral challenges during young adulthood. Participants will be randomly assigned to receive six sessions of GET or ISL over eight weeks. GET focuses on helping individuals set and pursue meaningful goals, regulate emotions related to cancer, and improve self-regulation skills. ISL provides supportive therapy through attentive listening and encouragement without directive advice. Both interventions are delivered individually via an interactive video platform to improve access. The study also explores how cultural factors like Familism and Acculturative Stress may influence outcomes. During the study, participants will complete assessments at baseline, immediately after the intervention, and three months later. Researchers will measure psychological outcomes such as anxiety, depression, spiritual well-being, career thoughts, and emotional coping, along with stress-sensitive biomarkers including inflammatory cytokines and salivary cortisol patterns. The study includes monitoring intervention feasibility and cultural influences. Participation will last about 20 weeks from baseline through follow-up.

Researchers are collecting detailed clinical and biological information from patients starting anticancer immunotherapy to better understand immune-related side effects that can affect various organs. The study aims to identify factors that increase the risk of these toxicities and to develop ways to prevent or manage them effectively. This observational study will help personalize future immunotherapy treatments by balancing benefits and risks for each patient. Participants receive immunotherapy drugs such as checkpoint inhibitors (including PD-1, PD-L1, CTLA4, and others) either alone or with other cancer treatments. Patients are enrolled before their first immunotherapy treatment and followed for up to 5 years or until they stop treatment permanently. The study also collects blood, plasma, serum, and immune cells samples before, during, and at the onset of immune-related side effects. During the study, participants will be regularly monitored through clinical evaluations and biological sample collections to track any immune-related toxicities. Researchers will estimate the incidence of these side effects over 10 years. Data collected will include clinical details and biological markers to support further research on mechanisms causing toxicity. This long-term follow-up helps improve understanding of immunotherapy safety and guides future patient care.

This research aims to improve understanding and treatment of cancer by creating an online platform where patients, doctors, and researchers can share medical information and research findings. The study tests the idea that this shared knowledge will help patients better understand their condition, support doctors in making treatment decisions, and speed up cancer research progress. The study involves cancer patients who have been diagnosed and are receiving medical care. Participants do not receive any active treatment as part of this observational study. Instead, leftover blood, bodily fluids, or tissue samples collected during routine clinical care will be analyzed. The results of these analyses will be shared on the All4Cure website to build a shared knowledge base accessible to patients, clinicians, and scientists. There are no experimental interventions or treatments administered. During the study, patients will contribute by allowing their leftover clinical samples to be used for research. Researchers will monitor changes in tumor molecular profiles over six years to learn more about cancer. Participants' health information will be shared anonymously on the platform to help accelerate research. The study does not involve additional treatments, and participation involves data sharing and sample analysis only.